Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ALKAL1 Biologics Sequence Review Report 2026: ALK and LTK ligand 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ALKAL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ALKAL2 Biologics Sequence Review Report 2026: ALK and LTK ligand 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ALKAL2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
AMHR2 Biologics Sequence Review Report 2026: Anti-Muellerian hormone type-2 receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AMHR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
AIRE Biologics Sequence Review Report 2026: Autoimmune regulator Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AIRE protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
AGTRAP Biologics Sequence Review Report 2026: Type-1 angiotensin II receptor-associated protein Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AGTRAP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
AGTR2 Biologics Sequence Review Report 2026: Type-2 angiotensin II receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AGTR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ALCAM Biologics Sequence Review Report 2026: CD166 antigen Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ALCAM protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
AGTR1 Biologics Sequence Review Report 2026: Type-1 angiotensin II receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AGTR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
AGER Biologics Sequence Review Report 2026: Advanced glycation end product-specific receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AGER protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADRM1 Biologics Sequence Review Report 2026: Proteasomal ubiquitin receptor ADRM1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADRM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADRB3 Biologics Sequence Review Report 2026: Beta-3 adrenergic receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADRB3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADRA2B Biologics Sequence Review Report 2026: Alpha-2B adrenergic receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADRA2B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
21
22
23
24
25
>>
1586
>